Hosted on MSN3mon
Here's Why Agios Stock Plummeted More Than 20% on Monday
alpha or beta-thalassemia, the ENERGIZE study evaluated the drug in non-transfusion-dependent (NTD) thalassemia patients. Alongside the oral presentation, Agios also disclosed that it has ...
Nasdaq1mon
Agios Pharmaceuticals Files for Regulatory Approval of Mitapivat for Thalassemia as Phase 3 RISE UP Study for Sickle Cell Disease Completes Enrollment
Here are some of the largest recent moves: Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in ... www.agios.com ) under the “Events & Presentations” tab.